Key facts
- It has raised $500K; the latest was Early Stage VC in Jan 2025.
- Notable investors include IndieBio, Connecticut Innovations, Mission BioCapital, MassBio, Yale Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for D2B3
- ·The full record, as it builds
Funding rounds
No funding rounds for D2B3 are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About D2B3
Operator of a pre-clinical biotechnology platform intended to advance drug delivery to the brain and central nervous system. The company offers proprietary technology that transiently and specifically opens the blood-brain barrier, enabling the targeting of CNS diseases with high efficacy, and providing a versatile, plug-and-play approach for most drugs and therapeutic classes.
- Sector
- Healthcare
- HQ
- New Haven, CT, United States
- Website
- d2b3.bio/
- Ownership
- Privately Held (backing)
D2B3 doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in D2B3 shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on D2B3 in its N-PORT filings yet. We sweep new filings monthly.